In NSCLC, fibroblast activation protein (FAP)-targeted agents such as [<sup>177</sup>Lu]Lu-FAP-2286 demonstrated partial metabolic responses, including a 44.4% response rate and 78% disease control in a mixed cohort. This evidence concerns the gene FAP and non-small cell lung carcinoma.